`
`CURRICULUM VITAE - DANIEL WILLIAM COYNE, M.D.
`
`
`
`
`
`
`
`May 14, 2020
`
`Personal Information
`Sex: Male
`Date of Birth: December 22, 1956
`Place of Birth: Cleveland Heights, Ohio
`
`
`Citizenship: U.S.
`
`Addresses and Telephone Numbers:
`
`
`Office:
`Chromalloy American Kidney Center
`660 South Euclid Avenue, Box 8129
`St. Louis, MO 63110-1093
`(314) 362-7211
`FAX: (314) 747-3743
`
`And
`
`Barnes-Jewish Dialysis Center
`4205 Forest Park Blvd.
`St. Louis, MO 63108
`
`
`Present Position:
`
`
`Professor of Medicine, Division of Nephrology
`Department of Medicine
`Washington University School of Medicine
`St. Louis, Missouri
`
`
`Education:
`
`Undergraduate:
`St. Louis University - B.A., Chemistry, August 1975 – May 1979
`St. Louis, MO
`
`
`
`
`
`
`
`Graduate:
`Case Western Reserve School of Medicine - M.D., August 1979 – May 1983
`Cleveland, Ohio
`
`Postgraduate:
`Intern, Emory University Medicine Program
`Atlanta, Georgia
`1983 - 1984
`
`Resident, Emory University Medicine Program
`Atlanta, GA
`1984 - 1986
`
`Fellow, Renal Division, Washington University School of Medicine
`St. Louis, MO
`1986 - 1989
`
`
`
`
`
`Academic Positions:
`Instructor in Medicine, Washington University School of Medicine
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`St. Louis, Missouri
`1989 - 1990
`
`Assistant Professor, Case Western Reserve School of Medicine
`Cleveland, Ohio
`1990 - 1993
`
`
`
`
`
`
`
`Assistant Professor of Medicine (Renal Diseases)
`Washington University School of Medicine
`St. Louis, Missouri
`1993 - 1997
`
`Associate Professor of Medicine (Renal Diseases)
`Washington University School of Medicine
`St. Louis, Missouri
`1997 - 2005
`
`Professor of Medicine, Division of Nephrology
`Washington University School of Medicine
`St. Louis, Missouri
`2005 - Present
`
`
`
`University and Hospital Appointments and Committees:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Attending Physician, Chromalloy American Kidney Center
`Barnes Hospital at Washington University Medical Center
`St. Louis, Missouri
`1989 - 1990
`
`Staff Physician, Cleveland Veteran's Administration
`Hospital, Cleveland, Ohio
`1990 - 1993
`
`Assistant Physician, Barnes Hospital at Washington University Medical Center
`St. Louis, Missouri
`1993 – Present
`
`Director of Hemodialysis, Chromalloy American Kidney Center
`Washington University School of Medicine
`1993 – 2015
`
`Renal Division Representative to the Fellowship Subcommittee of the Graduate Medical
`Education Committee
`1994- 2007
`
`Renal Division Representative to the Internal Medicine Practice Group Management
`Committee
`1994- Present
`
`Director of Renal Fellowship Program, Washington University School of Medicine and
`Barnes-Jewish Hospital
`1999 – 2007
`
`Director, Medical Multispecialty Outpatient Group at the Center for Advanced Medicine,
`Washington University School of Medicine
`2001 – Present
`
`Medical Director, Chromalloy American Kidney Center
`Washington University School of Medicine
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`2015 - Present
`
`
`
`Medical Licensure and Board Certification:
`
`
`American Board of Internal Medicine, 1986
`Subspecialty Examination, Nephrology, 1988
`National Board of Physicians and Surgeons, 2017
`
`
`Military Service: None
`
`Honors and Awards:
`
`
`Donahoe Award, Organic Chemistry, St. Louis University, 1978
`
`
`
`Midwest Trainee Award, American Federation of Clinical Research, 1989
`Certificate – Novo Nordisk, Inc – Clinical Trial Investigator, 12/2007
`
`
`Editorial Responsibilities:
`
`Editorial Board Member: Journal of the American Society of Nephrology (JASN) 2007- 2010
`
`Ad hoc reviewer, American Journal of Kidney Diseases (AJKD); Clinical Journal of the American
`Society of Nephrology (CJASN); Kidney International (KI); Kidney International Reports;
`Hemodialysis International; Nephrology, Dialysis, and Transplantation (NDT); American Journal of
`Nephrology (AJN); Journal of the American Medical Association (JAMA); New England Journal of
`Medicine (NEJM).
`
`
`Professional Societies and Organizations:
`
`
`American Society of Nephrology
`International Society of Nephrology
`
`Consulting Relationships and Board Memberships:
`
`
`Member, NIH Data Safety Monitoring Board, (DSMB) for the PACTTE – Partnership for
`Anemia: Clinical and Translational Trials in the Elderly, National Institute on Aging, National
`Institute of Health, USA
`
`Member, NIH Data Safety Monitoring Board, (DSMB) for CKD-MBD – Chronic Kideny
`Diseases – Metabolic Bone Disease Trials for the NIDDK, USA
`
`Consultant, Cardiovascular and Renal Drugs Advisory Committee (CRDAC), Center for
`Drug Evaluation and Research (CDER), Food and Drug Administration, USA
`
`Consultant to Fresenius Medical Care-Renal Care Group, Medibeacon, Glaxo Smith Kline,
`Astra Zeneca, and Novadiol
`
`
`
`Research Support:
`
`
`Selected Previous and Active Studies
`1. U01 DK 49240-01 Co-investigator, Mortality and Morbidity in Hemodialysis HEMO
`Study) Patients, 9/30/94 - 12/31/01
`2. R&D labs 9803 and 9806
`Principal Investigator, Ferrlecit trial, IV iron in Hemodialysis;
`Double blind and open label trials,9/1/99 – 10/1/00
`3. Watson FERR2004 Lead National Chairman, and Principal Investigator of DRIVE study; a
`randomized trial to assess the efficacy of intravenous iron in anemic dialysis patients with
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`ferrtin > 500 and TSAT < 25%. 11/1/04 – 6/1/06
`4. Hospira EPOE-10-01 Principal Investigator; A Therapeutic Equivalence Study Comparing
`the Efficacy and safety of Intravenous Epoetin Hospira and Epoetin alfa (Amgen) in Patients
`with Chronic Renal Failure Requiring Hemodialysis. 2011 to 2014
`5. Deltanoid Principal Investigator and Lead Investigator on the PK study; A Phase 2A, Open-
`label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in
`Secondary Hyperparathyroidism in Patients on Hemodialysis. 2012- 2015.
`
`
`
`
`Independent Research (Active)
`
`
`1 FGCL-4592-Study 063
`
`2. FGCL-4592-Study 060
`
`3. CREDENCE Trial
`
`Site Principal Investigator, in the Phase 3 Correction of
`Anemia in Incident HD Patients using Roxadustat vs
`Epoetin
`Site Principal Investigator, in the Phase 3 Correction of
`Anemia in CKD-ND Patients using Roxadustat vs
`placebo
`Site Principal Investigator, in a Randomized, Placebo-
`controlled trial of Canagliflozin on Renal and
`Cardiovascular Outcomes in Type 2 Diabetics
`4. ZS-005, ZS Pharma Site Principal Investigator in a 12 month Phase 3 Maintenance
`Study of ZS-9 in patients with Hyperkalemia
`5. Medibeacon ORFM Pilot 2 Sole Principal Investigator of A Pilot Safety and
`Pharmacokinetic Study of MB-102 versus Iohexol and
`the Use of the Non-invasive Optical Renal Function
`Monitor (ORFM) device, in Subjects with Normal and
`Impaired Renal Function and a Range of Skin Color
`Types
`Three related trials of daprodustat for CKD-related
`anemia. I am the site PI for all three trials.
`
`6. GSK HIF Activator
`
`
`Clinical Title and Responsibilities:
`
`
`Assistant Professor of Medicine
`Case Western Reserve School of Medicine
`Cleveland, Ohio
`1990 - 1993
`
`Staff Physician
`Cleveland Veteran's Administration Hospital
`Cleveland, Ohio
`1990 - 1993
`
`Assistant Professor of Medicine
`Washington University School of Medicine
`St. Louis, Missouri
`1993 – 1997
`
`
`
`
`
`Co-Director, Renal Fellowship Training Program
`Renal Division, Department of Medicine
`Washington University School of Medicine
`1993 – 1999
`
`Director of Hemodialysis, Chromalloy American Kidney Center
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`Washington University School of Medicine
`St. Louis, Missouri
`1993 - 2017
`
`Instructor, Clinical Medicine II Program
`Washington University School of Medicine
`1996 - 2000
`
`Associate Professor of Medicine
`Washington University School of Medicine
`St. Louis, Missouri
`1997 – 2005
`
`Director, Renal Fellowship Training Program
`Renal Division, Department of Medicine
`Washington University School of Medicine
`1999 – 2007
`
`Coursemaster, Fourth Year Renal Medical Student Elective
`Renal Division, Department of Medicine
`Washington University School of Medicine
`1999 – 2007
`
`Director, Outpatient Renal Clinics
`Internal Medicine Practice Group
`Washington University School of Medicine
`1993 - Present
`
`Member, Advisory Council for BJC/WUMS Renal Network
`Barnes-Jewish Hospital and Washington University School of Medicine
`1999 - Present
`
`Director, Internal Medicine Multispecialty Outpatient Center
`Center for Advanced Medicine
`Washington University School of Medicine
`2000 – Present
`
`Professor of Medicine
`Washington University School of Medicine
`St. Louis, Missouri
`2005 – present
`
`Medical Director, Chromalloy American Kidney Center
`Washington University School of Medicine
`St. Louis, Missouri
`2017 – present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`
`Peer Reviewed Articles:
`
`1.
`
`Bibliography
`
`Coyne DW, Mordhorst M, Bertrand W, Morrison AR: Inhibition of bradykinin induced
`increases of Cytosolic Ca++ by a novel amiloride analog. J Pharm Exp Therap 1989;
`250:795-799
`
`
`2.
`
`
`3.
`
`
`4.
`
`
`5.
`
`
`6.
`
`
`7.
`
`
`8.
`
`
`9.
`
`
`10.
`
`Coyne DW, Mordhorst M, Bertrand W, Morrison AR: Bradykinin stimulated PGE2
`production is independent of changes in intracellular calcium in MDCK cells. Biochem
`Biophys Res Comm 1989; 161:1333-1340
`
`Coyne DW, Mordhorst M, Morrison AR: Regulation of eicosanoid biosynthesis by phorbol
`ester in Madin Derby canine kidney cells. Am J Physiol 1990; 259:F698-F703
`
`Coyne DW, Morrison AR: Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1
`stimulated PGE2 production in mesangial cells. Biochem Biophys Res Comm 1990;
`173:718-724
`
`Coyne DW, Nickols M, Bertrand W, Morrison AR: Regulation of mesangial cell
`cyclooxygenase synthesis by cytokines and glucocorticoids. Am J Physiol 1992; 263:F97-
`102
`
`Coyne DW, Dunn MJ, Mimran A: Angiotensin converting enzyme inhibition and the kidney.
`ACE Report 1993; 100:21-27
`
`Kaetzel DM, Coyne DW, Fenstermaker RA: Transcriptional control of the platelet-derived
`growth factor subunit genes. Biofactors 1993; 4:71-81
`
`Kaetzel Jr DM, Maul RS, Liu B, Bonthron D, Fenstermaker RA, Coyne DW: Platelet-
`derived growth factor A-chain gene transcription is mediated by positive and negative
`regulatory regions in the promoter. Biochem J 1994; 301:321-327
`
`Coyne DW, Lowell JA, Windus DW, Delmez JA, Shenoy S, Audrain J, Howard TK:
`Comparison of survival of an expanded PTFE graft designed for early cannulation to
`standard wall PTFE grafts. J Am Coll Surgery 1996; 183: 401-405
`
`Coyne DW, Delmez J, Spence G, Windus DW: Impaired delivery of hemodialysis
`prescriptions: An analysis of causes and an approach to evaluation. J Am Society
`Nephrology 1997.
`
`
`11. Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M: Increased
`plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 82:847-
`850, 1997
`
`
`
`12.
`
`
`
`13.
`
`
`14.
`
`
`15.
`
`Vesely TM, Hovsepian DM, Pilgram TK, Coyne DW, Shenoy S: Upper extremity central
`venous obstruction in hemodialysis patients: treatment with wallstents. Radiology 204:343-
`348, 1997.
`
`Coyne DW, Dagogo-Jack S, Klein S, Merabet E, Audrain J, Landt M: High-Flux Dialysis
`Lowers Plasma Leptin Concentration in Chronic Dialysis Patients. Amer. J. Kid. Dis.
`32:1031-1035, 1998
`
`Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne DW: Hyperleptinemia in patients
`with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis.
`Peritoneal Dialysis International. 18:34-40, 1998
`
`Landt M. Brennan DC. Parvin CA. Flavin KS. Dagogo-Jack S. Coyne DW.
`Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation.
`Nephrology, Dialysis, Transplantation. 13(9):2271-2275, 1998
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`16.
`
`Coyne, DW, Yelton, S, Long, C, Preston, C, and Taylor, LF. Network 12 Hepatitis B
`vaccination quality improvement program: An educational program directed at physicians,
`staff, and patients. Adv. In Renal Replacement Therapy 7 (S1): S71-S75, 2000.
`
`
`17.
`
`Beindorff, ME, Larkin, KM, Coyne, DW, Sicard, GA, Shenoy, S, Lowell, JA, Howard, TK,
`Landt, M. Variation in plasma leptin concentrations after unilateral nephrectomy.
`Metabolism, 51:206-210, 2002.
`
`
`18. Michael, B, Coyne, DW, Fishbane, S, et al. Sodium Ferric Gluconate in Hemodialysis
`Patients: Adverse reactions compared to Placebo and Iron Dextran. Kidney Int. 61:1830-
`1839, 2002
`
`
`19.
`
`
`20.
`
`
`21.
`
`
`22.
`
`
`23.
`
`
`24.
`
`
`25.
`
`
`26.
`
`
`27.
`
`Koch, M, Coyne, D, Vesely, T. Bacterial Colonization of Chronic Hemodialysis Catheters:
`Evaluation with Endoluminal Brushes and Heparin Aspirate. J. Vasc. Access, 3:38-42, 2002
`
`Coyne DW. Letter to the Editor: Parenteral iron safety and the special article “just the FAQs:
`Frequently asked questions about iron and anemia in patients with chronic kidney disease”
`Amer J Kidney Dis 40:219, 2002
`
`Coyne DW, Grieff M, Ahya S, Giles K, Norwood K, Slatopolsky E. Differential Effects of
`Acute Administration of 19-Nor-1a,25-Dihydroxyvitamin D2 and 1a,25-Dihydroxyvitamin
`D3 on Serum Calcium and Phosphorus in Hemodialysis Patients. Amer Kidney Dis
`40(6):1283-8, 2002.
`
`Brown AJ and Coyne DW, Vitamin D Analogs For The Treatment Of Secondary
`Hyperparathyroidism In Chronic Renal Failure, Treatments in Endocrinology 1(5): 313-327,
`2002.
`
`Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B,
`Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, and Warnock DG. Sodium
`Ferric Gluconate Complex in Hemodialysis Patients: II. Adverse Reactions in Iron Dextran-
`Sensitive and Iron Dextran-Tolerant Patients. Kidney Int. 63:217-224, 2003.
`
`Agarwal R. Nissenson AR. Batlle D. Coyne DW. Trout JR. Warnock DG. Prevalence,
`treatment, and control of hypertension in chronic hemodialysis patients in the United States.
`American Journal of Medicine. 115(4):291-7, 2003
`
`Folkert V, Michael B, Agarwal R, Coyne DW, Dahl N, Myirski P, and Warnock DG.
`Chronic Use of Sodium Ferric Gluconate Complex in Hemodialysis Patients: Safety of
`Higher Dose (≥ 250 mg) Administration. Amer J Kidney Dis. 41(3):651-7, 2003.
`
`Allon M, Depner T, Radeva M, Bailey J,Beddhu S, Butterly D, Coyne D, Gassman J,
`Kaufman A, Kaysen G, Lewis J, Schwab S, for the HEMO Study Group: Impact of Dialysis
`Dose and Membrane on Infection-Related Hospitalization and Death: Results of the HEMO
`Study. J Amer Soc Nephrol 14(7):1863-1870, 2003.
`
`Belani SS. Goldberg AC. Coyne DW. Ability of non-high-density lipoprotein cholesterol and
`calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk
`factors in dialysis patients. American Journal of Kidney Diseases. 43(2):320-9, 2004.
`
`
`28. Michael B. Coyne DW. Folkert VW. Dahl NV. Warnock DG. Ferrlecit Publication
`Committee. Sodium ferric gluconate complex in haemodialysis patients: a prospective
`evaluation of long-term safety. Nephrology Dialysis Transplantation. 19(6):1576-80, 2004
`
`
`29.
`
`
`30.
`
`Coyne DW. Letter to the Editor: Labile iron in parenteral iron formulations: a quantitative
`and comparative study. Nephrol Dial Transplant.19(10):2674-5, 2004
`
`Block GA. Martin KJ. de Francisco AL. Turner SA. Avram MM. Suranyi MG. Hercz G.
`Cunningham J. Abu-Alfa AK. Messa P. Coyne DW. Locatelli F. Cohen RM. Evenepoel P.
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`
`31.
`
`
`32.
`
`Moe SM. Fournier A. Braun J. McCary LC. Zani VJ. Olson KA. Drueke TB. Goodman WG.
`Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.[see
`comment]. New England Journal of Medicine. 350(15):1516-25, 2004
`
`Allon, M, Radeva, M, Bailey, J, Beddhu, S, Butterly, D, Coyne, DW, Depner, TA, Gassman,
`JJ, Kaufman, AM, Kaysen, GA, Lewis, JA & Schwab, SJ: The spectrum of infection-related
`morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant, 20:1180-6, 2005.
`
`Staniforth, ME, Cheng, SC & Coyne, DW: Once-weekly intravenous paricalcitol in the
`treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol, 63:454-
`60, 2005.
`
`
`33. Michael B, Fishbane S, Coyne DW, Agarwal R, and Warnock D. Safety of intravenous iron
`supplementation with sodium ferric gluconate complex. Nature Clin Pract Nephrol 2: 92-
`100, 2006
`
`
`34.
`
`
`35.
`
`
`36.
`
`
`37.
`
`
`38.
`
`
`39.
`
`40.
`
`41.
`
`42.
`
`
`43.
`
`
`44.
`
`
`45.
`
`
`46.
`
`Coyne DW. Acharya M. Qiu P Abboud H Batlle D. Rosansky S. Fadem S. Levine B.
`Williams L. Andress D. Sprague S. Paricalcitol Capsule for the Treatment of Secondary
`Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Amer J Kidney Dis 47:263-
`76, 2006
`
`Joist H. Brennan DC. Coyne DW. Anemia in the Renal Transplant Patient. Adv Chronic
`Kidney Dis 13:4-10, 2006
`
`Cheng S, Coyne DW. Paricalcitol capsules for the control of secondary hyperparathyroidism
`in chronic kidney disease. Expert Opinion on Pharmacotherapy. 7(5):617-21, 2006
`
`Brown A.J., Koch M.J., Coyne D.W. Oral Feeding Acutely Down-Regulates Serum PTH in
`Hemodialysis Patients Nephron Clin Pract 103:c106-113, 2006
`
`Joist H. Ahya SN, Giles K, Norwood K, Slatopolsky E, and Coyne DW. Differential Effects
`of Very High Doses of Doxercalciferol and Paricalcitol on Serum Phosphorus in
`Hemodialysis Patients. Clin Nephrol 65:335-41, 2006
`
`Abboud H. Coyne DW. Smolenski O. Anger M. Lunde N. Qiu P. Hippensteel R. Pradhan
`RS. Palaparthy RV. Kavanaugh A. Melnick J. Williams L. Batlle D. Secondary
`Hyperparathyroidism in Stage 3 and 4 Chronic Kidney Disease: Comparison of Oral
`Paricalcitol Dosing Regimens. Amer J Nephrol 26: 105-14, 2006
`
`Coyne, D: Challenging the boundaries of anemia management: a balanced approach to I.V.
`iron and EPO therapy. Kidney Int Suppl:S1-3, 2006.
`
`Coyne, D: Iron indices: what do they really mean? Kidney Int Suppl:S4-8, 2006.
`
`Cheng, S, Coyne, D: Paricalcitol capsules for the control of secondary hyperparathyroidism
`in chronic kidney disease. Expert Opin Pharmacother, 7:617-21, 2006.
`
`Coyne, D: Influence of Industry on Renal Guideline Development. Clin J Amer Soc Nephrol,
`2:3-7, 2007
`
`Coyne, D: Practice Recommendations Based on Low, Very Low, and Missing Evidence.
`Clin J Amer Soc Nephrol, 2:11-12, 2007
`
`Saab G, Young DO, Gincherman Y, Giles K, Norwood K, and Coyne DW. Prevalence of
`Vitamin D Deficiency and the Safety and Effectiveness of Monthly Ergocalciferol in
`Hemodialysis Patients. Nephron Clin Pract 105:c132–c138, 2007
`
`Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, and the
`DRIVE Study Group, Ferric Gluconate is Highly Efficacious in Anemic Hemodialysis
`Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`
`47.
`
`
`48.
`
`
`49.
`
`50.
`
`
`51.
`
`Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Amer Soc Nephrol
`18: 975-984, 2007
`
`Cheng S, Coyne D. Vitamin D and outcomes in chronic kidney disease. Current Opinion in
`Nephrology & Hypertension 16(2):77-82, 2007
`
`Singh AK, Coyne Dw, Shapiro W, Rizkala AR, and the DRIVE Study Group. Predictors of
`Response to Anemia Treatment in Hemodialysis Patients with High Serum Ferritin and Low
`Transferrin Saturation: Lessons from the Dialysis Patients’ Response to IV Iron with
`Elevated Ferritin (DRIVE) Study. Kidney Int. 71:1163–1171, 2007
`
`Coyne DW. Use of Epoetin in Chronic Renal Failure. JAMA. 297:1713-1716, 2007
`
`Zheng S, Nath V, and Coyne DW. ACE Inhibitor-Based, Directly Observed Therapy for
`Hypertension in Hemodialysis Patients. Am J Nephrol 27:522–529, 2007
`
`Brancaccio D, Bommer J, and Coyne DW. Vitamin D Receptor Activator Selectivity in the
`Treatment of Secondary Hyperparathyroidism: Understanding the Differences Among
`Therapies. Drugs. 67(14):1-18, 2007
`
`
`52. Wish JB, Coyne DW. Use of Erythropoiesis-Stimulating Agents in patients With Anemia of
`Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic
`Limitations of Existing Therapies. Mayo Clin Proc 82(11): 1371-1380, 2007.
`
`
`53.
`
`
`54.
`
`
`55.
`
`
`56.
`
`
`57.
`
`
`58.
`
`
`59.
`
`60.
`
`
`61.
`
`Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S,
`Adamis H, Beyer U. C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with
`Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. Am J
`Nephrol 28:280–289, 2007 DOI: 10.1159/000111115
`
`Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC,
`Dahl NV, and Coyne DW. Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis
`Patients with Elevated Ferritin. J Am Soc Nephrol 19: 372–379, 2008. doi:
`10.1681/ASN.2007050606
`
`Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM.
`Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
`Endocrine Pract 14(1): 18-27, 2008
`
`Cheng, S, Young D, Huang Y, Delmez J, and Coyne DW. A Randomized, Double-Blind,
`Placebo-controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis
`Patients. Clin J Amer Soc Nephrol 3:1131-1138, 2008
`
`Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, and Henry DH.
`High-Molecular weight Iron Dextran: A Wolf in Sheep’s Clothing? J Amer Soc Nephrol
`19(5):833-4, 2008
`
`Coyne DW: From Anemia Trials to Clinical Practice: Understanding the Risks and Benefits
`When Setting Goals for Therapy. Semin in Dial. 21(3): 212–216, 2008
`
`Coyne DW. Letter to the Editor: Relative Mortality and Epoetin Alfa Dose Among
`Hemodialysis Patients. Amer J Kidney Dis 51(5):866-7, 2008
`
`Coyne DW. Cinacalcet Should Not Be Used to Treat Secondary Hyperparathyroidism in
`Stage 3–4 Chronic Kidney Disease. Nature Clin Pract Nephrol 4, 364-365, 2008
`
`Coyne DW. Letter to the Editor: Vitamin D Compounds in Chronic Kidney Disease. Annals
`of Internal Medicine. 148(12):969-70, 2008
`
`
`62. Malluche HH. Monier-Faugere MC. Wang G. Fraza O JM. Charytan C. Coburn JW. Coyne
`DW. Kaplan MR. Baker N. McCary LC. Turner SA. Goodman WG. An assessment of
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`
`63.
`
`64.
`
`65.
`
`66.
`
`
`67.
`
`68.
`
`
`69.
`
`
`70.
`
`
`71.
`
`72.
`
`
`73.
`
`74.
`
`75.
`
`76.
`
`77.
`
`78.
`
`in dialysis patients with secondary
`cinacalcet HCl effects on bone histology
`hyperparathyroidism. Clin Nephrol 69(4):269-78, 2008
`
`Coyne DW Letter to the Editor: The TREAT Study Answers a Question, Not The Question.
`Amer J Kidney Dis 52(3): 626-633, 2008
`
`Dahl NV, Henry DH, Coyne DW. Thrombosis with Erythropoietic Stimulating Agents—
`Does Iron-Deficient Erythropoiesis Play a Role? Semin in Dial. 21(3):210–211, 2008
`
`Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK. Ferric gluconate treatment provides
`cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 74:
`1588–1595, 2008
`
`Coyne DW. A Comprehensive Vision of IV iron Therapy. Amer J Kidney Dis 52:6 (Suppl
`1): S14-S20, 2008
`
`Auerbach M, Coyne DW, Ballard H. IV iron: From Anathema to Standard of Care. Am. J.
`Hematol. 83:580–588, 2008.
`
`Coyne DW Letter to the Editor: Conflicts of Interest and Viewpoint Bias in KDOQI and
`KDIGO Workgroups. Nephrol Dial Transplant 2008 23(12):4071, 2008
`
`Coyne DW, Trout JR, Kapoian T. Comment on "Does ferric gluconate lower epoetin
`requirements in hemodialysis patients with high ferritin levels?" Nature Clin Pract Nephrol
`(2008) 4, E1 (on-line only) doi:10.1038/ncpneph0965
`
`Coyne DW, Sims A, Bingel B. Results of an Anemia Management Program to Reduce High
`Epoetin Doses by Targeted Use of IV Ferric Gluconate. Nephrol Nursing J 35(6); 583-587,
`2008
`
`Zheng S, Coyne DW, Joist H, Schuessler R, Godboldo-Brooks A, Ercole P, and Brennan
`DB. Iron Deficiency Anemia and Iron Losses after Renal Transplantation. Transplant Int 22:
`434–440, 2009
`
`Provenzano R, Schiller B, Rao M, Coyne D, Brenner L,and Pereira BJG. Ferumoxytol as an
`Intravenous Iron Replacement Therapy in Hemodialysis Patients. Clin J Amer Soc Nephrol
`4: 386–393, 2009
`
`Coyne DW. Managing Anemia in For-Profit Dialysis Chains: When Ethics and Business
`Conflict. Semin in Dial 22(1): 18–21, 2009
`
`Ford BA, Coyne DW, Eby CS, and Scott MG. Variability of ferritin measurements in
`chronic kidney disease; implications for iron management. Kidney Int 75:104-110, 2009
`
`Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant anemia:
`the role of sirolimus. Kidney Int. 2009 Kidney International 76:376–382, 2009
`
`Coyne, DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic
`kidney disease. Expert Opinion on Pharmacotherapy 10:2563-2568, 2009
`
`Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma
`phosphorus levels in peritoneal dialysis patients Perit Dial Int. 29(5):562-7, 2009
`
`Lambers Heerspinka HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya
`P, Amdahl MJ, Andress DL, de Zeeuw D. The Selective Vitamin D Receptor Activator for
`Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. Am J
`Nephrol 30:280-286, 2009
`
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`79.
`
`80.
`
`81.
`
`82.
`
`83.
`
`84.
`
`85.
`
`86.
`
`87.
`
`Coyne, DW, Brennan, DC. Seeking Safe and Efficacious Anemia Management. Semin. in
`Dial. 22(5):590-1, 2009
`
`Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, and M Wolf. Vitamin D
`deficiency and anemia in early chronic kidney disease. Kidney Int. 77: 715-720, 2010
`
`Coyne DW, and M Auerbach. Anemia management in chronic kidney disease: Intravenous
`iron steps forward. Amer J Hematology Am. J. Hematol. 85:311–312, 2010
`
`Coyne DW. It’s Time to Compare Anemia Management Strategies in Hemodialysis. Clin J
`Amer Soc Nephrol 5: 740–742, 2010
`
`London G, Coyne Dw, Hruska K, Malluche H, Martin K. The New Kidney Disease:
`Improving Global Outcomes (KDIGO) Guidelines – Expert Clinical Focus on Bone and
`Vascular Calcification. Clin Nephrol 2010
`
`Sprague SM. Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor
`agonists in chronic kidney disease. Clin J Amer Soc Nephrol. 5(3):512-8, 2010
`
`Ford BA, Eby CS, Scott MG, and Coyne DW. Intra-individual variability in serum hepcidin
`precludes its use as a marker of iron status in hemodialysis patients. Kidney Int advance
`online publication, July 28, 2010; doi:10.1038/ki.2010.254 (2010)
`
`Besarab A, and Coyne DW. Iron supplementation to treat anemia in patients with chronic
`kidney disease. Nat. Rev. Nephrol. 6, 699–710, 2010
`
`Camins BC, Richmond AM, Dyer KL, Zimmerman HN, Coyne DW, Rothstein MR, and
`Fraser VJ. A Crossover intervention trial evaluating the efficacy of a chlorhexidine-
`impregnated sponge (Biopatch) to reduce catheter-related bloodstream infections in
`hemodialysis patients. Infect Control Hosp Epidemiol. 31:1118-1123, 2010
`
`Coyne DW. The future of IV iron in Nephrology. Nephrol. Dial. Transplant. 4 [Suppl 1]: i6–
`i9, 2011
`
`Coyne DW. Hepcidin: Clinical Utility as a Diagnostic Tool and Therapeutic Target. Kidney
`Int 80, 240–244, 2011
`
`Coyne DW. Health-Related Quality of Life was Not Improved by Targeting Higher
`Hemoglobin in the Normal Hematocrit Trial. Kidney Int. 82: 235–241, 2012
`
`91. Wang X, Belani S, Coyne DW, Fabbrini E, Reeds DN, Patterson BW, Mittendorfer B, Klein
`S. Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease.
`Cardiorenal Med 2:57-65, 2012
`
`Brown AJ, Coyne DW. Bioavailable D in Chronic Kidney Disease. Kidney Int. 82:5-7, 2012.
`
`Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitol on calcium
`and phosphate metabolism and markers of bone health in patients with diabetic nephropathy:
`results of the VITAL study. Nephrol. Dial. Transplant. 28(9): 2260-2268, 2013.
`
`Larson DS, and Coyne DW. Understanding and exploiting hepcidin as an indicator of
`anemia due to chronic kidney disease. Kidney Res and Clin Pract 32: 11-15, 2013
`
`Gupta DR, Larson DS, Thomsen LL, and Coyne DW. Pharmacokinetics of Iron Isomaltoside
`1000 in patients with stage 5 chronic kidney disease on dialysis therapy. Drug Metab &
`Toxicology 4:3-8, 2013.
`
`92.
`
`88.
`
`89.
`
`90.
`
`93.
`
`94.
`
`95.
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`97.
`
`98.
`
`96.
`
`
`Coyne DW. Anemia management in dialysis: why the FDA and CMS have it right (and how
`KDIGO got it wrong) Nephrol News & Issues Feb 27(2):16 – 20, 2013.
`
`Coyne DW. Letter to the Editor: The KDOQI US Commentary on KDIGO Anemia
`Guideline and Quality of Life. Amer J Kidney Dis. X:XX – XX, 2014.
`
`Coyne DW. Anemia in CKD: Treating the Numbers, Not the Patients. JAMA Internal
`Medicine 174(5):708-709, 2014
`
`Larson DS, Coyne DW. Update on Intravenous Iron Choices. Curr Opin Nephrol
`Hypertension 23:186-191, 2014.
`
`100. Scott MG, Coyne DW. Should We Sweat the Small (Micro) Things? Clin Chemistry 60:435-
`437, 2014.
`
`101. Coyne DW, Goldberg S, Faber M, Ghossein C, and Sprague SM. A Randomized Multicenter
`Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stage 3-4 CKD.
`Clin J Am Soc Nephrol 9: 1620-1626, 2014.
`
`99.
`
`
`102. Coyne DW, Delos Santos, R. Evaluating the Safety and Rationale for Cinacalcet Post-
`Transplant Hyperparathyroidism and Hypercalcemia. Amer J Transplant 14:2446–2447,
`2014
`
`103. Bandari S, Kalra P, Kothari J, Ambul P, Christensen JH, Essaian AM, Thomsen LL,
`Macdougall IC, and Coyne DW. A randomized, open-label trial of iron isomaltoside 1000
`(Monfer) compared with iron sucrose (Venofer) as maintenance therapy in hemodialysis
`patients. Nephrol Dial Transplant 30 (9): 1577-1589, 2015
`
`104. Vijayan A, Li T, Dusso A, Jain S, DW Coyne. Relationship of 1,25 dihydroxy Vitamin D
`Levels to Clinical Outcomes in Critically Ill Patients with Acute Kidney Injury. J Nephrol
`Ther. 5:190-193, 2015.
`
`105. Charytan DM, Barton Pai A, Chan CT, Coyne DW, Hung AM, Kovesdy CP, and S. Fishbane
`on behalf of the Dialysis Advisory Group of the American Society of Nephrology.
`Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. J Am
`Soc Nephrol 26: 1238-1247, 2015.
`
`106. Pandey R, Zella J, Clagett-Dame M, Plum LA, DeLuca HF and Coyne DW. Use of 2MD, a
`Novel Oral Calcitriol Analog,
`in Hemodialysis Patients with Secondary
`Hyperparathyroidism. Am J Nephrol 43:213-220, 2016.
`
`107. Pandey R, Daloul R, Coyne DW: Iron Treatment Strategies in Dialysis-Dependent CKD.
`Semin Nephrol 36(2):105-111, 2016.
`
`108. Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne
`DW: A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-
`dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant
`31(4):646-655, 2016.
`
`109. Coyne DW, Ficocello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C,
`Maddux FW, Kossman RJ, and Sprague SM. Real-world effectiveness of sucroferric
`oxyhydroxide in patients on hemodialysis: A retrospective analysis of pharmacy data. Clin
`Nephrol. 2017 DOI 10.5414/CN109021
`
`110. Ritter C, Miller B, Coyne DW, Gupta D, Zheng S, Brown AJ, and E. Slatopolsky.
`Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil content in patients
`
`

`

`Curriculum Vitae - Daniel W. Coyne, M.D.
`Continued
`
`
`with chronic kidney disease. Kidney Int. (2017) https://doi.org/10.1016/j.kint.2017.05.003
`
`111. Coyne DW. Commentary: Iron Overload in Dialysis Patients: Rust or Bust? Kidney Int.
`Reports, Kidney Int Rep (2017) 2, 995–997; http://dx.doi.org/10.1016/j.ekir.2017.08.014
`
`112. Pandey R, Zella JB, Zhu JG, Plum LA, Clagett-Dame M, Blaser WJ, Bedale W, DeLuca HF
`and Coyne DW. Pharmacokinetics of a new oral vitamin D receptor activator (2-methylene-
`19-Nore-(20S) 1a, 25-Dihydroxyvitamin D3) in patients with crhonic kidney disease and
`secondary hyperparathyroidism on hemodialysis. Drugs Res Develop 17:597–605, 2017.
`DOI 10.1007/s40268-017-0210-z
`
`
`113. Coyne DW, and Kovesdy CP. Changing the paradigms for the treatment of chronic kidney
`disease. Kidney Int. Suppl. 7(3):155-156, 2017
`
`114. Coyne DW, Goldsmith D, and MacDougall IC. New options for the anemia of chronic
`kidney disease. Kidney Int. Suppl. 7(3):157-163, 2017. doi.org/10.1016/j.kisu.2017.09.002
`
`115. Chakinala MM, Coyne DW, Benza RL,Frost AE, McGoon MD, Hartline BK, Frantz RP,
`Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in
`pulmonary arterial hypertension: a REVEAL registry analysis. J Heart Lung transplantation
`37: 696-705, 2018 doi.org/10.1016/j